Incyte INCY
NASDAQ INCY
$127.59 -0.41 (-0.32%)
As of: Sep 4, 2026 · 3:20 PM EDT

Incyte (INCY) Cash from Financing Activities (2010 - 2026)

Incyte's (INCY) quarterly Cash from Financing Activities came in at $65.5 million in Q2 2026, up 682.04% YoY from $8.4 million in Q2 2025, and down 22.83% on a QoQ basis from $84.8 million in Q1 2026.

Analysis

Incyte (INCY) Cash from Financing Activities (2010 - 2026) Analysis & Trends

Incyte (INCY) has 17 years of Cash from Financing Activities data on file, last reported at $65.5 million in Q2 2026.

  • Quarterly Cash from Financing Activities rose 682.04% year-over-year to $65.5 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $275.2 million (up 867.13% YoY) and the FY2025 annual result came in at $101.0 million, up 105.0% from the prior year.
  • Cash from Financing Activities slipped to $65.5 million in Q2 2026, from $84.8 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $137.7 million in Q4 2025 to a low of -$2.0 billion in Q2 2024.
  • A 5-year average of -$99.5 million and a median of -$1.2 million in 2022 frame the typical range for Cash from Financing Activities.
  • The widest YoY moves for Cash from Financing Activities: up 5794.22% in 2024, down 15620.49% in 2024.
  • Tracing INCY's Cash from Financing Activities over 5 years: stood at -$2.5 million in 2022, then soared by 113.95% to $346000.0 in 2023, then soared by 5794.22% to $20.4 million in 2024, then soared by 575.39% to $137.7 million in 2025, then slumped by 52.48% to $65.5 million in 2026.
  • The last three Cash from Financing Activities figures came in at $65.5 million (Q2 2026), $84.8 million (Q1 2026), and $137.7 million (Q4 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Vertex Pharmaceuticals 138.43 Bn 130.58 Bn 2.84 Bn -426.70 Mn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn -1.22 Bn
3 Argenx Se 63.34 Bn 58.15 Bn 1.37 Bn -
4 Moderna 57.98 Bn 52.85 Bn 52.00 Mn 14.00 Mn
5 Revolution Medicines 43.98 Bn 43.98 Bn - 2.42 Bn
6 BeOne Medicines 39.92 Bn 34.82 Bn 1.53 Bn -6.05 Mn
7 Alnylam Pharmaceuticals 35.42 Bn 32.11 Bn 992.69 Mn 36.24 Mn
8 Royalty Pharma 28.42 Bn 27.58 Bn - -273.15 Mn
9 Insmed 27.36 Bn 26.20 Bn 358.27 Mn 27.18 Mn
10 Incyte 25.57 Bn 21.03 Bn 1.57 Bn 65.46 Mn
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 65.46 Mn
Mar 31, 2026 84.82 Mn
Dec 31, 2025 137.74 Mn
Sep 30, 2025 -12.78 Mn
Jun 30, 2025 -11.25 Mn
Mar 31, 2025 -12.68 Mn
Dec 31, 2024 20.39 Mn
Sep 30, 2024 -32.35 Mn
Jun 30, 2024 -2.00 Bn
Mar 31, 2024 -12.41 Mn
Dec 31, 2023 346,000.00
Sep 30, 2023 -37.26 Mn
Jun 30, 2023 12.87 Mn
Mar 31, 2023 4.01 Mn
Dec 31, 2022 -2.48 Mn
Sep 30, 2022 -14.31 Mn
Jun 30, 2022 15.90 Mn
Mar 31, 2022 96,000.00
Dec 31, 2021 9.01 Mn
Sep 30, 2021 -19.34 Mn